Genexine gets Orphan designation for GHD therapy

Genexine Inc. (KOSDAQ:095700) said FDA granted Orphan Drug designation to the company's GX-H9 to treat growth hormone deficiency (GHD).

The company expects full data this year from a Phase II trial of GX-H9 to treat adult GHD, and interim data in 1H17 from a Phase II trial of GX-H9 to treat pediatric GHD...